Applied StemCell, Inc.

Applied StemCell, Inc. is a biotechnology company specializing in advanced cell therapy solutions, offering innovative products and services to support researchers and developers in the field. Founded in 2008 by Ruby Chen-Tsai, Applied StemCell, Inc. is headquartered in Milpitas, US.

The company focuses on advanced cell therapy solutions and has engaged in five funding deals. It was recently acquired by QHP Capital in October 2023 from a group of investors, including Virtus Inspire Ventures, Ping An Ventures, Hermed Capital, and BioSciKin. The total amount raised by the company is USD 19. 00 mn, with the latest funding round being a Grant of USD 2.

00 mn. Applied StemCell specializes in advanced cell therapy solutions, providing a range of innovative products and services for researchers in the biotechnology sector. Key offerings include the TARGATT™ hypoimmunogenic hiPSC knock-in kit, ActiCells™ GMP hiPSCs, and gene editing services for induced pluripotent stem cells (iPSCs) and mammalian cell lines, facilitating custom disease model development and gene editing. Applied StemCell generates revenue through direct sales and service contracts with business-to-business clients in the life sciences sector.

Its flagship offerings like TARGATT™ iPSCs and cGMP iPSC cell banking services are often procured on a fee-for-service basis, tailored to meet client-specific needs across diverse projects and services. The acquisition by QHP Capital in October 2023 aims to support Applied StemCell's vision of enhancing the market for future cell gene therapy through the production of iPSCs and associated cell products. The company plans to introduce new products that align with this vision and expand its operations into new geographic regions, although specific markets have not been disclosed. Recent funding will be pivotal in driving these initiatives forward.